文献速递胸部肿瘤放疗放疗物理与技术

三维剂量分布影像组学预测肺癌放疗毒性

Radiomics analysis of 3D dose distributions to predict toxicity of radiotherapy for lung cancer.
PubMed 文献 · Radiother Oncol · 2020-11-06

该研究回顾性纳入167例接受放疗的肺癌患者,从三维剂量图提取影像组学特征,构建临床、临床+DVH、临床+DVH+影像组学三层模型预测≥2级急慢性肺毒性和急性食管毒性。结果显示联合影像组学模型在训练集和测试集中均表现更优,提示剂量图影像组学可超越传统临床和DVH模型。

要点

  • 剂量图影像组学联合临床和DVH可提升急性肺毒性预测。
  • 联合模型对晚期肺毒性预测优于临床或临床+DVH模型。
  • 急性食管毒性预测提升幅度相对有限。

核心结论

  • 在放疗肺癌患者中,从三维剂量图提取的影像组学特征在预测急性肺毒性和晚期肺毒性方面似乎优于基于临床因素和DVH的常规模型。

研究设计与样本

  • 回顾性收集2015至2018年接受放疗的167例肺癌患者,急性与晚期毒性按CTCAE v4.0评分。
  • 从三维剂量图提取影像组学特征,同时纳入DVH和常规临床因素,用神经网络在70%患者中增量训练三种毒性预测模型。
  • 经1000次自助法确定基于Youden指数的 optimal cut-off 值,在剩余30%患者中以平衡准确率(BAcc)评估模型。

主要发现

  • 167例中非小细胞肺癌占78%、小细胞肺癌占14%、其他组织学占8%,治疗时中位年龄66岁。
  • 分别有22.2%、16.8%和30.0%的患者发生急性肺毒性、晚期肺毒性和急性食管毒性。
  • 训练集(n=117)中,临床仅/临床+DVH/联合模型预测急性肺毒性的BAcc分别为0.68/0.79/0.92,晚期肺毒性为0.66/0.77/0.87,急性食管毒性为0.68/0.73/0.84。
  • 测试集(n=50)中,对应BAcc分别为急性肺毒性0.69/0.69/0.92,晚期肺毒性0.76/0.80/0.89,急性食管毒性0.58/0.73/0.72。

关键数值与推荐

  • 毒性分级采用CTCAE v4.0,预测目标为≥2级急性肺毒性、≥2级晚期肺毒性和≥2级急性食管毒性。
  • 训练集与测试集按70%与30%划分,模型评估指标为平衡准确率(BAcc)。
  • 联合模型在测试集中预测急性肺毒性的BAcc为0.92,晚期肺毒性为0.89,急性食管毒性为0.72。

临床怎么用

  • 对于接受放疗的肺癌患者,可考虑在临床和DVH基础上加入三维剂量图影像组学特征以提升急性与晚期肺毒性预测。
  • 该研究结果支持进一步验证剂量图影像组学模型在放疗毒性预测中的附加价值。

局限性

  • 研究为单中心回顾性设计,样本量有限。
  • 毒性预测模型仅在内部训练集和测试集中评估,尚无外部验证。
  • 急性食管毒性预测的增益相对有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: (Chemo)-radiotherapy (RT) is the gold standard treatment for patients with locally advanced lung cancer non accessible for surgery. However, current toxicity prediction models rely on clinical and dose volume histograms (DVHs) and remain unsufficient. The goal of this work is to investigate the added predictive value of the radiomics approach applied to dose maps regarding acute and late toxicities in both the lungs and esophagus. METHODS: Acute and late toxicities scored using the CTCAE v4.0 were retrospectively collected on patients treated with RT in our institution. Radiomic features were extracted from 3D dose maps considering Gy values as grey-levels in images. DVH and usual clinical factors were also considered. Three toxicity prediction models (clinical only, clinical + DVH and combined, i.e., including clinical + DVH + radiomics) were incrementally trained using a neural network on 70% of the patients for prediction of grade ≥2 acute and late pulmonary toxicities (APT/LPT) and grade ≥2 acute esophageal toxicities (AET). After bootstrapping (n = 1000), optimal cut-off values were determined based on the Youden Index. The trained models were then evaluated in the remaining 30% of patients using balanced accuracy (BAcc). RESULTS: 167 patients were treated from 2015 to 2018: 78% non small-cell lung cancers, 14% small-cell lung cancers and 8% other histology with a median age at treatment of 66 years. Respectively, 22.2%, 16.8% and 30.0% experienced APT, LPT and AET. In the training set (n = 117), the corresponding BAcc for clinical only/clinical + DVH/combined were 0.68/0.79/0.92, 0.66/0.77/0.87 and 0.68/0.73/0.84. In the testing evaluation (n = 50), these trained models obtained a corresponding BAcc of 0.69/0.69/0.92, 0.76/0.80/0.89 and 0.58/0.73/0.72. CONCLUSION: In patients with a lung cancer treated with RT, radiomic features extracted from 3D dose maps seem to surpass usual models based on clinical factors and DVHs for the prediction of APT and LPT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Bourbonne V, Da-Ano R, Jaouen V, et al. Radiomics analysis of 3D dose distributions to predict toxicity of radiotherapy for lung cancer. Radiother Oncol. 2020. PMID: 33161012. doi:10.1016/j.radonc.2020.10.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。